

**SENATE
STATE OF MINNESOTA
NINETY-SECOND SESSION**

S.F. No. 215

(SENATE AUTHORS: CLAUSEN, Hoffman, Tomassoni and Abeler)

DATE
01/21/2021

D-PG
128

Introduction and first reading
Referred to Health and Human Services Finance and Policy

OFFICIAL STATUS

1.1 A bill for an act
1.2 relating to health; establishing a pharmacogenomics grant program; proposing
1.3 coding for new law in Minnesota Statutes, chapter 144.

1.4 BE IT ENACTED BY THE LEGISLATURE OF THE STATE OF MINNESOTA:

1.5 Section 1. **[144.1477] PHARMACOGENOMICS (PGX) GRANT PROGRAM.**

1.6 Subdivision 1. **Grants.** Within limits of available appropriations, the commissioner of
1.7 health shall award grants to persons, organizations, and entities that apply for a grant under
1.8 this subdivision to fund research studies on the evidence needed to: (1) support payer
1.9 reimbursement and funding of PGx testing; (2) determine and validate new PGx variants
1.10 in diverse populations such as Native Americans and Somali groups; (3) determine ethical,
1.11 legal, and social implications of PGx; (4) determine the technical aspects needed to protect
1.12 data and privacy as it relates to PGx; and (5) determine the education needed for successful
1.13 PGx implementation.

1.14 Subd. 2. **Allocation of grants.** To receive a grant under this section, an applicant must
1.15 submit an application on a form and in the manner specified by the commissioner of health.
1.16 The applicant must submit the application by the deadline established by the commissioner.
1.17 The commissioner shall require at a minimum the following information from the applicant:

1.18 (1) a description of achievable objectives, a work plan, budget, budget narrative, a project
1.19 communication plan, a timeline for implementation and completion of processes or projects
1.20 enabled by the grant, and an assessment of privacy and security issues and a proposed plan
1.21 to address the issues specified in subdivision 1;

2.1 (2) a plan for how patients and consumers will be involved in development of policies
2.2 and procedures related to the access and interchange of relevant information;

2.3 (3) a plan for documenting and evaluating results of the grant; and

2.4 (4) a plan for use of data exchange standards as the data relates to sharing testing results,
2.5 including standardized terminology to be used when sharing data.

2.6 Subd. 3. **Eligible grantees.** Persons, organizations, and entities eligible to receive grant
2.7 funding under this section include those that:

2.8 (1) have expertise in pharmacogenomics;

2.9 (2) are expert data analysts in the pharmacogenomics market; and

2.10 (3) specialize in pharmacogenomic research.

2.11 Subd. 4. **Consultation.** In awarding grants under subdivision 1, the commissioner shall
2.12 follow the grants management protocols in section 16B.97 and consult with interested parties
2.13 who are able to provide technical information, advice, and recommendations on grant
2.14 projects and awards. Interested parties include but are not limited to persons or private and
2.15 public entities with expertise in pharmacogenomics.